Brief: Concord Biotech Ltd Received Approval From USFDA For Mycophenolate Mofetil For Oral Suspension USP, 200 Mg/Ml
02/06/2026 12:06
BRIEF-Concord Biotech Ltd Received Approval From USFDA For Mycophenolate Mofetil For Oral Suspension USP, 200 Mg/Ml June 2 (Reuters) - Concord Biotech Ltd CONB.NS:
CONCORD BIOTECH LTD- RECEIVED APPROVAL FROM USFDA FOR ITS ANDA FOR MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION USP, 200 MG/ML
Source text: ID:nBSE79MRKK
Further company coverage: CONB.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Concord Biotech
See all newsIndia's Concord Biotech rises after board to consider bonus share issue
Brief: Concord Biotech Ltd June-Quarter Consol Net Profit 585.3 Million Rupees
Brief: Concord Biotech Completes PPB (Kenya) And NDA (Uganda) Inspection At Unit-Ii Formulation Facility
Brief: Concord Biotech Completes Anvisa Inspection At Limbasi API Manufacturing Facility
India's Concord Biotech jumps to 4-month high after US FDA drug approval